PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Price In Tune With Revenues
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Price In Tune With Revenues
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) price-to-sales (or "P/S") ratio of 19x might make it look like a strong sell right now compared to the Medical Equipment industry in the United States, where around half of the companies have P/S ratios below 3.3x and even P/S below 1.2x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.
What Does PROCEPT BioRobotics' P/S Mean For Shareholders?
With revenue growth that's superior to most other companies of late, PROCEPT BioRobotics has been doing relatively well. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. If not, then existing shareholders might be a little nervous about the viability of the share price.
Keen to find out how analysts think PROCEPT BioRobotics' future stacks up against the industry? In that case, our free report is a great place to start.How Is PROCEPT BioRobotics' Revenue Growth Trending?
PROCEPT BioRobotics' P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.
If we review the last year of revenue growth, the company posted a terrific increase of 82%. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.
Looking ahead now, revenue is anticipated to climb by 43% per year during the coming three years according to the eight analysts following the company. That's shaping up to be materially higher than the 10% each year growth forecast for the broader industry.
With this in mind, it's not hard to understand why PROCEPT BioRobotics' P/S is high relative to its industry peers. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
What Does PROCEPT BioRobotics' P/S Mean For Investors?
Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
We've established that PROCEPT BioRobotics maintains its high P/S on the strength of its forecasted revenue growth being higher than the the rest of the Medical Equipment industry, as expected. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless these conditions change, they will continue to provide strong support to the share price.
And what about other risks? Every company has them, and we've spotted 3 warning signs for PROCEPT BioRobotics you should know about.
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
與美國醫療設備行業相比,PROCEPT BioRobotics Corporation(納斯達克股票代碼:PRCT)的19倍市銷率(或 “市盈率”)可能使其看起來像是強勁的拋售。在美國,大約一半的公司的市銷率低於3.3倍,甚至市盈率低於1.2倍也很常見。但是,僅按面值計算市銷率是不明智的,因爲可以解釋其爲何如此之高。
PROCEPT BioRobotics的市銷率對股東意味着什麼?
PROCEPT BioRobotics最近的收入增長優於大多數其他公司,因此表現相對較好。看來許多人預計強勁的收入表現將持續下去,這提高了市銷率。否則,現有股東可能會對股價的可行性感到有些擔憂。
想了解分析師如何看待PROCEPT BioRobotics的未來與行業背道而馳嗎?在這種情況下,我們的免費報告是一個很好的起點。PROCEPT BioRobotics 的收入增長趨勢如何?
PROCEPT BioRobotics的市銷率對於一家預計將實現非常強勁的增長,而且重要的是,其表現要好於行業的公司來說是典型的。
如果我們回顧一下去年的收入增長,該公司公佈了82%的驚人增長。得益於其令人難以置信的短期表現,最近三年的總體收入也實現了驚人的增長。因此,我們可以首先確認該公司在這段時間內在增加收入方面做得非常出色。
根據關注該公司的八位分析師的說法,展望未來,預計未來三年收入每年將增長43%。這將大大高於整個行業每年10%的增長預期。
考慮到這一點,不難理解爲何PROCEPT BioRobotics的市銷率高於同行。顯然,股東們並不熱衷於轉移可能着眼於更繁榮未來的東西。
PROCEPT 生物機器人公司的市銷率對投資者意味着什麼?
通常,我們傾向於限制使用市銷率來確定市場對公司整體健康狀況的看法。
我們已經確定,PROCEPT BioRobotics之所以保持其較高的市銷率,是因爲其預測的收入增長將高於醫療設備行業的其他部門。看來股東對公司未來的收入充滿信心,這支撐了市銷率。除非這些條件發生變化,否則他們將繼續爲股價提供強有力的支撐。
那其他風險呢?每家公司都有它們,我們已經發現了你應該知道的3種PROCEPT BioRobotics警告信號。
當然,具有良好收益增長曆史的盈利公司通常是更安全的選擇。因此,您可能希望看到這些免費收集的市盈率合理且收益增長強勁的其他公司。
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧